131 related articles for article (PubMed ID: 28087326)
1. Autoimmune lymphoproliferative syndrome caused by homozygous FAS mutations with normal or residual protein expression.
Agrebi N; Sfaihi Ben-Mansour L; Medhaffar M; Hadiji S; Fedhila F; Ben-Ali M; Mekki N; Hachicha M; Barsaoui S; Barbouche MR; Ben-Mustapha I
J Allergy Clin Immunol; 2017 Jul; 140(1):298-301.e3. PubMed ID: 28087326
[No Abstract] [Full Text] [Related]
2. Complete CD95/FAS deficiency due to complex homozygous germline TNFRSF6 mutations in an adult patient with mild autoimmune lymphoproliferative syndrome (ALPS).
Tessarin G; Mazza C; Baronio M; Gazzurelli L; Rossi S; Moratto D; Badolato R; Rensing-Ehl A; Ehl S; Warnatz K; Rosanelli C; Morello E; Plebani A; Lougaris V
Clin Immunol; 2021 Jul; 228():108757. PubMed ID: 33992756
[No Abstract] [Full Text] [Related]
3. Autoimmune Lymphoproliferative Syndrome-FAS Patients Have an Abnormal Regulatory T Cell (Treg) Phenotype but Display Normal Natural Treg-Suppressive Function on T Cell Proliferation.
Mazerolles F; Stolzenberg MC; Pelle O; Picard C; Neven B; Fischer A; Magerus-Chatinet A; Rieux-Laucat F
Front Immunol; 2018; 9():718. PubMed ID: 29686686
[TBL] [Abstract][Full Text] [Related]
4. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
5. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
[TBL] [Abstract][Full Text] [Related]
6. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation.
Xie Y; Pittaluga S; Price S; Raffeld M; Hahn J; Jaffe ES; Rao VK; Maric I
Haematologica; 2017 Feb; 102(2):364-372. PubMed ID: 27846610
[TBL] [Abstract][Full Text] [Related]
9. Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome.
Rensing-Ehl A; Pannicke U; Zimmermann SY; Lorenz MR; Neven B; Fuchs I; Salzer U; Speckmann C; Strauss A; Maaβ E; Collet B; Enders A; Favier R; Alessi MC; Rieux-Laucat F; Zieger B; Schwarz K; Ehl S
Blood; 2015 Oct; 126(16):1967-9. PubMed ID: 26472737
[No Abstract] [Full Text] [Related]
10. Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection.
Nomura K; Kanegane H; Otsubo K; Wakiguchi H; Noda Y; Kasahara Y; Miyawaki T
Int J Hematol; 2011 Jun; 93(6):760-764. PubMed ID: 21626105
[TBL] [Abstract][Full Text] [Related]
11. Pearls and pitfalls: Autoimmune lymphoproliferative syndrome and autoimmune lymphoproliferative syndrome-like disease.
Bartels AK; Banks TA; Bay JL
Allergy Asthma Proc; 2017 Jul; 38(4):317-321. PubMed ID: 28668112
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults.
Lambotte O; Neven B; Galicier L; Magerus-Chatinet A; Schleinitz N; Hermine O; Meyts I; Picard C; Godeau B; Fischer A; Rieux-Laucat F
Haematologica; 2013 Mar; 98(3):389-92. PubMed ID: 22983577
[TBL] [Abstract][Full Text] [Related]
13. Investigation of common variable immunodeficiency patients and healthy individuals using autoimmune lymphoproliferative syndrome biomarkers.
Roberts CA; Ayers L; Bateman EA; Sadler R; Magerus-Chatinet A; Rieux-Laucat F; Misbah SA; Ferry BL
Hum Immunol; 2013 Dec; 74(12):1531-5. PubMed ID: 23993982
[TBL] [Abstract][Full Text] [Related]
14. Synergistic defects of novo FAS and homozygous UNC13D leading to autoimmune lymphoproliferative syndrome-like disease: A 10-year-old Chinese boy case report.
Gu H; Ma J; Chen Z; Wang J; Zhang R; Wu R
Gene; 2018 Sep; 672():45-49. PubMed ID: 29864493
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune Lymphoproliferative Syndrome Presenting with Invasive Streptococcus pneumoniae Infection.
Oksenhendler E; Spaan AN; Neven B; Stolzenberg MC; Fusaro M; Casanova JL; Rieux-Laucat F; Boisson B; Magérus A
J Clin Immunol; 2020 Apr; 40(3):543-546. PubMed ID: 32144537
[No Abstract] [Full Text] [Related]
16. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome.
Janda A; Schwarz K; van der Burg M; Vach W; Ijspeert H; Lorenz MR; Elgizouli M; Pieper K; Fisch P; Hagel J; Lorenzetti R; Seidl M; Roesler J; Hauck F; Traggiai E; Speckmann C; Rensing-Ehl A; Ehl S; Eibel H; Rizzi M
Blood; 2016 May; 127(18):2193-202. PubMed ID: 26907631
[TBL] [Abstract][Full Text] [Related]
17. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis.
Pensati L; Costanzo A; Ianni A; Accapezzato D; Iorio R; Natoli G; Nisini R; Almerighi C; Balsano C; Vajro P; Vegnente A; Levrero M
Gastroenterology; 1997 Oct; 113(4):1384-9. PubMed ID: 9322534
[TBL] [Abstract][Full Text] [Related]
18. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
[TBL] [Abstract][Full Text] [Related]
19. A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect.
Simesen de Bielke MG; Yancoski J; Rocco C; Pérez LE; Cantisano C; Pérez N; Oleastro M; Danielian S
J Clin Immunol; 2012 Dec; 32(6):1197-203. PubMed ID: 22752343
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune pancreatitis in the autoimmune lymphoproliferative syndrome (ALPS): a sheep in wolves' clothing?
Langan RC; Gill F; Raiji MT; Mullinax JE; Pittaluga S; Pandalai P; Davis J; Perkins K; Avital I; Rudloff U
Pancreas; 2013 Mar; 42(2):363-6. PubMed ID: 23407489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
